You are here: Industry Insights > Migraine

News List

Aimovig approved by EU for migraine prevention europeanpharmaceuticalreview
April 19, 2019
Researchers found that more than one quarter (26 per cent) of patients taking Aimovig 70mg were migraine free after month 15…
Migraine drug developer Biohaven considering potential sale firstwordpharma
April 14, 2019
According to people familiar with the matter, Biohaven Pharmaceutical is examining its options……
Migraine Pain Linked to Raised Suicide Risk drugs
April 11, 2019
People with migraine may be much more likely to attempt suicide than others, a new study suggests.
Allergan files anti-CGRP migraine drug in the US pharmatimes
March 12, 2019
US regulators have accepted for review Allergan’s application to market ubrogepant for the acute treatment of migraine.
Satsuma Provides Update, Prepares to Advance Lead Product Candidate, STS101 americanpharmaceuticalreview
February 22, 2019
Satsuma Pharmaceuticals provided a corporate update, including recent progress with its development of STS101 for the acute treatment of migraine.....
Biohaven Reaches Targeted Therapeutic Exposures of BHV-3500 americanpharmaceuticalreview
February 19, 2019
Biohaven announced that administration of intranasal BHV-3500 in a Phase 1 clinical trial has achieved targeted therapeutic exposures and that the compound will advance into a Phase 2 trial to evaluate efficacy for the acute treatment of migraine....
Lilly asks migraine patients to use their imaginations in first DTC push for Emgality fiercepharma
February 18, 2019
Eli Lilly’s first effort for migraine drug Emgality had a personal connection for the director of the TV commercial.
NICE draft guidance rejects use of Novartis' CGRP inhibitor Aimovig for preventing migraine firstwordpharma
January 10, 2019
The National Institute for Health and Care Excellence issued draft guidance Thursday recommending against routine NHS use of Novartis' Aimovig (erenumab) for preventing migraine. The agency determined that the injectable CGRP receptor antagonist, which co
European Commission approves Lilly's Emgality for migraine pharmatimes
November 22, 2018
Eli Lilly has confirmed that Emgality, a once-monthly monoclonal antibody injection, has been approved by the European Commission for preventive treatment of migraine in adults who have at least four migraine days per month.
Lilly files lasmiditan for migraine pharmatimes
November 19, 2018
Eli Lilly has filed an application in the US to market lasmiditan for the acute treatment of migraine with or without aura in adults.

Previous page 1 2 3 4 5 6 7 8 9 Next page